To market, to market - 2002

被引：20

作者：

Boyer-Joubert, C ^{[1
]}

Lorthiois, E ^{[1
]}

Moreau, F ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, Fresnes, France

来源：

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38 | 2003年 / 38卷

关键词：

D O I：

10.1016/S0065-7743(03)38034-0

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：347 / 374

页数：28

共 162 条

[1]

*AD INT LTD, 2001, DRUGS THERAPY PERSPE, V17, P4

[2]

Agarwal A, 2001, IDrugs, V4, P26

[3] Corneal opacities associated with NTBC treatment [J].

Ahmad, S ;

Teckman, JH ;

Lueder, GT .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2002, 134 (02) :266-268

[4] Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I [J].

Al-Dhalimy, M ;

Overturf, K ;

Finegold, M ;

Grompe, M .

MOLECULAR GENETICS AND METABOLISM, 2002, 75 (01) :38-45

[5]

Atarashi H., 1993, Cardiovascular Drugs and Therapy, V7, P444

[6] Favorable outcome of hereditary tyrosinemia type 1 induced liver failure with NTBC treatment. [J].

Barkaoui, E ;

Debray, D ;

Habès, D ;

Ogier, H ;

Bernard, O .

ARCHIVES DE PEDIATRIE, 1999, 6 (05) :540-544

[7] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].

Barker, AJ ;

Gibson, KH ;

Grundy, W ;

Godfrey, AA ;

Barlow, JJ ;

Healy, MP ;

Woodburn, JR ;

Ashton, SE ;

Curry, BJ ;

Scarlett, L ;

Henthorn, L ;

Richards, L .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914

[8] Tiotropium bromide [J].

Barnes, PJ .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (04) :733-740

[9] Ezetimibe [J].

Bays, H .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (11) :1587-1604

[10] To market, to market -: 2001 [J].

Bernardelli, P ;

Gaudillière, B ;

Vergne, F .

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 37, 2002, 37 :257-277

← 1 2 3 4 5 6 7 8 9 10 →